Biocon (NSE:BIOCON) Beneish M-Score: -2.32 (As of Jul. 02, 2026)


NSE:BIOCON Biocon Ltd NSE:BIOCON
85 GF Score
Price ₹418.60
GF Value ₹339.27
Valuation Modestly Overvalued
! 10 Warning Signs
View Full Analysis

What is Biocon Beneish M-Score?

Biocon NSE:BIOCON +0.10% 85 Beneish M-Score is -2.32 as of Jul. 02, 2026. GuruFocus rates NSE:BIOCON with a GF Score™ of 85/100 and a GF Value™ of ₹339.27 (Modestly Overvalued). The stock has 10 warning signs investors should review. Among 829 Biotechnology companies, Biocon ranks worse than 51.87% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.32 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Biocon's Beneish M-Score or its related term are showing as below:

NSE:BIOCON' s Beneish M-Score Range Over the Past 10 Years
Min: -2.86   Med: -2.32   Max: -1.15
Current: -2.32

During the past 13 years, the highest Beneish M-Score of Biocon was -1.15. The lowest was -2.86. And the median was -2.32.


Biocon Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Biocon's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biocon Beneish M-Score Chart

Biocon Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.32 -1.15 -2.25 -2.86 -2.32

Biocon Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.86 0.00 0.00 0.00 -2.32

NSE:BIOCON vs VRTX, REGN, ALNY: Beneish M-Score Comparison

For the Biotechnology subindustry, Biocon's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biocon Beneish M-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biocon's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Biocon's Beneish M-Score falls into.


NSE:BIOCON
85GF Score
Biocon Ltd NSE:BIOCON
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biocon Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Biocon for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.9617+0.528 * 0.9907+0.404 * 1.0166+0.892 * 1.1148+0.115 * 0.9369
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0+4.679 * -0.025269-0.327 * 0.8585
=-2.32

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was ₹59,868 Mil.
Revenue was ₹167,799 Mil.
Gross Profit was ₹110,892 Mil.
Total Current Assets was ₹171,798 Mil.
Total Assets was ₹636,506 Mil.
Property, Plant and Equipment(Net PPE) was ₹146,635 Mil.
Depreciation, Depletion and Amortization(DDA) was ₹19,567 Mil.
Selling, General, & Admin. Expense(SGA) was ₹0 Mil.
Total Current Liabilities was ₹140,692 Mil.
Long-Term Debt & Capital Lease Obligation was ₹112,833 Mil.
Net Income was ₹3,856 Mil.
Gross Profit was ₹0 Mil.
Cash Flow from Operations was ₹19,940 Mil.
Total Receivables was ₹55,843 Mil.
Revenue was ₹150,522 Mil.
Gross Profit was ₹98,547 Mil.
Total Current Assets was ₹162,862 Mil.
Total Assets was ₹587,973 Mil.
Property, Plant and Equipment(Net PPE) was ₹136,078 Mil.
Depreciation, Depletion and Amortization(DDA) was ₹16,870 Mil.
Selling, General, & Admin. Expense(SGA) was ₹12,720 Mil.
Total Current Liabilities was ₹143,338 Mil.
Long-Term Debt & Capital Lease Obligation was ₹129,445 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(59868 / 167799) / (55843 / 150522)
=0.356784 / 0.370996
=0.9617

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(98547 / 150522) / (110892 / 167799)
=0.654702 / 0.660862
=0.9907

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (171798 + 146635) / 636506) / (1 - (162862 + 136078) / 587973)
=0.499717 / 0.491575
=1.0166

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=167799 / 150522
=1.1148

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(16870 / (16870 + 136078)) / (19567 / (19567 + 146635))
=0.110299 / 0.11773
=0.9369

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(0 / 167799) / (12720 / 150522)
=0 / 0.084506
=0

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((112833 + 140692) / 636506) / ((129445 + 143338) / 587973)
=0.398307 / 0.463938
=0.8585

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(3856 - 0 - 19940) / 636506
=-0.025269

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Biocon has a M-score of -2.32 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.32 mean?
Biocon (NSE:BIOCON) has a Beneish M-Score of -2.32 as of Jul. 02, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Biocon and its competitors. According to the industry distribution chart, Biocon ranks #430 out of 829 companies in the Biotechnology industry, placing it in the top 51.9%.
Is Biocon's Beneish M-Score too high?
Biocon's current Beneish M-Score is -2.32. Based on the distribution chart, Biocon ranks #430 out of 829 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Biocon has a GF Score™ of 85/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Biocon's Beneish M-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Biocon ranks #430 out of 829 companies for Beneish M-Score. This places Biocon in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Biotechnology company?
A good Beneish M-Score depends on the Biotechnology industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Biocon and its competitors. Biocon's current Beneish M-Score is -2.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biocon stock overvalued right now?
Based on GuruFocus' analysis, Biocon (NSE:BIOCON) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹339.27, compared to a current price of ₹418.60 — trading 23.4% above its estimated fair value. The current Beneish M-Score is -2.32. Biocon's overall GF Score™ is 85/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Biocon (NSE:BIOCON), the current Beneish M-Score is -2.32 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biocon (NSE:BIOCON) Overvalued in 2026?

Based on GuruFocus' analysis, Biocon stock appears to be overvalued. The current stock price of ₹418.60 is trading 23.4% above its estimated GF Value™ of ₹339.27. GuruFocus considers Biocon to be Modestly Overvalued.

Key valuation signals for NSE:BIOCON:

  • Beneish M-Score: -2.32
  • GF Value™: ₹339.27 vs. price of ₹418.60 (23.4% above fair value)
  • GF Score™: 85/100 with 10 warning signs

No single metric tells the full story. See the NSE:BIOCON stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Biocon Business Description

Other Exchanges 532523:India
Address 20th KM, Hosur Road, Electronics City, Bengaluru, KA, IND, 560100
Biocon Ltd is a biopharmaceutical company that develops biotechnology therapies for diseases. The company is focused on developing, manufacturing, and supplying novel and biosimilar pharmaceuticals for diabetes, cancer, and autoimmune conditions. Biocon has four reportable segments: Biosimilars which derives maximum revenue, Generics, Novel Biologics (Novels), and Research services (Research). The company provides integrated contract research and manufacturing services to pharmaceutical and biotechnology companies through its subsidiary Syngene. Geographically, the company generates a majority of its revenue from its customers located in India and the rest from Brazil, Singapore, and the rest of the world.
85GF Score

Get the complete analysis for NSE:BIOCON

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹418.60
Price
₹339.27
GF Value